How much does a box of tepotinib cost in China?

Tepotinib is a targeted therapy for the treatment of metastatic non-small cell lung cancer (NSCLC) carrying exon 14 skipping mutations of the mesenchymal epidermal transforming factor receptor (MET). Since its official launch in China in 2021, tepotinib has provided patients with a new treatment option. However, the drug is not currently included in China's basic medical insurance list, leaving patients to bear the cost of the drug themselves.

In the domestic market, the price of tepotinib is relatively high, about more than 30,000 yuan per box. The high cost of drugs is a heavy financial burden for many patients and their families, limiting their widespread clinical application. When purchasing tepotinib, patients need to go to the local hospital pharmacy to inquire about the specific price and availability. Since availability and prices may vary slightly across pharmacies, the actual purchase price may vary.

To cope with high drug costs, some patients may seek lower-priced alternatives, such as generic drugs produced abroad. The price of generic Tepotinib drugs produced in Laos is relatively cheap, about more than 9,000 yuan per box, and the drug ingredients are basically the same as the domestic original drugs. These generic drugs provide a viable option for patients with limited financial resources and can alleviate financial pressure to a certain extent.

Although tepotinib has shown significant efficacy in the treatment of METExon14 skipping mutationNSCLC, its high price makes it unaffordable for many patients. In order to solve this problem, the government and medical institutions should actively promote the inclusion of innovative drugs such as tepotinib in the medical insurance catalog to reduce the financial burden on patients and improve drug accessibility and equity. At the same time, various payment methods and assistance programs need to be explored to help patients get the treatment they need.

If the disease is not currently covered by medical insurance, patients and their families should communicate closely with their doctors to understand all possible treatment options and resources, including clinical trials, charitable assistance, and international drug purchase channels, to obtain the best treatment effect and quality of life. Only through multi-party efforts can we ensure that more patients can afford and use these advanced treatments.